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Abstract
Background: Clostridium botulinum and related clostridia express extremely potent toxins known as botulinum neurotoxins
(BoNTs) that cause severe, potentially lethal intoxications in humans. These BoNT-producing bacteria are categorized in
seven major toxinotypes (A through G) and several subtypes. The high diversity in nucleotide sequence and genetic
organization of the gene cluster encoding the BoNT components poses a great challenge for the screening and
characterization of BoNT-producing strains.
Methodology/Principal Findings: In the present study, we designed and evaluated the performances of a resequencing
microarray (RMA), the PathogenId v2.0, combined with an automated data approach for the simultaneous detection and
characterization of BoNT-producing clostridia. The unique design of the PathogenID v2.0 array allows the simultaneous
detection and characterization of 48 sequences targeting the BoNT gene cluster components. This approach allowed
successful identification and typing of representative strains of the different toxinotypes and subtypes, as well as the
neurotoxin-producing C. botulinum strain in a naturally contaminated food sample. Moreover, the method allowed fine
characterization of the different neurotoxin gene cluster components of all studied strains, including genomic regions
exhibiting up to 24.65% divergence with the sequences tiled on the arrays.
Conclusions/Significance: The severity of the disease demands rapid and accurate means for performing risk assessments
of BoNT-producing clostridia and for tracing potentials sources of contamination in outbreak situations. The RMA approach
constitutes an essential higher echelon component in a diagnostics and surveillance pipeline. In addition, it is an important
asset to characterise potential outbreak related strains, but also environment isolates, in order to obtain a better picture of
the molecular epidemiology of BoNT-producing clostridia.
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Introduction
Botulism is a severe neuroparalytic disease caused by botulinum
toxin, and characterized by acute descending flaccid paralysis. The
disease is caused by consumption of food contaminated with pre-
formed toxin (foodborne botulism), or by absorption of toxin
produced in situ in wounds (wound botulism) or colonized
intestinal tracts (infant/intestinal adult botulism) [1]. Botulinum
neurotoxins (BoNT) are the most potent toxins known and are
considered as one of the six highest risk threat agents of
bioterrorism [2],[3].
BoNT are produced by six physiologically and genetically
distinct bacteria, namely Clostridium botulinum Groups I to IV,
and occasionally strains of C. butyricum and C. barati [4,5]. These
neurotoxin-producing bacteria can be further categorized in seven
major toxinotypes (A, B, C, D, E, F and G) based on the antigenic
properties of the toxins they produce [6],[7]. Toxinotypes A, B, E
and more rarely F are responsible for human botulism cases, while
infections by C and D toxinotypes are observed mainly in animals.
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Although most strains produce only one toxin, bivalent strains
producing two different toxins (Ab, Af, Ba, and Bf) have also been
reported [8–11]. In addition, C. botulinum strains producing a single
toxin but carrying a silent gene for another (A(B)) [10], and strains
producing a chimeric neurotoxin (C/D or D/C) have been
described [12].
The genes encoding the neurotoxins (bont) can be found on the
chromosome, a plasmid or a bacteriophage, and are located in a
cluster with other genes encoding associated non-toxic proteins
(ANTPs) forming the botulinum neurotoxin complexes [13]. The
recent sequencing of the bont genes has revealed significant
sequence variations within the toxinotypes and has led to the
recognition of several subtypes, with differences ranging between
2–32% at the amino acid level [14]. In addition, the BoNT gene
cluster varies in structure and organization [5], leading to the
differentiation of two different conserved cluster types, termed the
‘‘ha cluster’’ and the ‘‘orf-X cluster’’ (Figure 1). The ‘‘ha cluster’’
consists of a set of hemaglutinin (HA) genes while the ‘‘orf-X
cluster’’ consists of a set of genes of unknown function called ‘‘orf-
Xs’’ associated to the bont gene. The diversity in nucleotide
sequence and genetic cluster organization can be explained by the
occurrence of many recombination and insertion events [15], as
well as bont gene transfer between some toxinotypes of C. botulinum,
and with non-botulinum species [7].
This variability not only has implications for antibody
neutralization strategies [14], but also poses a great challenge for
screening and characterization of BoNT-producing strains.
Sensitive laboratory detection techniques are necessary for
establishing monitoring programs to track C. botulinum contami-
nation in animals, food and environmental samples. In addition,
characterization methods are essential for tracing potentials
sources of contamination in outbreak situations or forensic
investigations, and for performing molecular risk assessments of
BoNT-producing clostridia. Moreover, characterization of genetic
differences allows the development of improved diagnostics and
therapeutic agents for the treatment of botulism [14]. In
consequence, efforts have been centered on the development of
molecular techniques allowing simultaneous detection and typing
of C. botulinum toxinotypes, such as multiplex real time PCR and
focused DNA microarray [16,17][17–19]. These assays are highly
sensitive but rely on hybridization of sequence-specific primers for
sufficient DNA amplification and/or on a limited number of
probes for detection of target genomic regions, and may therefore
be suboptimal when bacterial sequence divergence is high. In
addition, although some multiplex assays allow simultaneous
detection and differentiation of toxinotype A subtypes and strains
[16,20], they do not allow typing further than the toxin type or in-
depth genetic characterization of strains belonging to other known
toxinotypes. Several genotyping methods such as pulse-field gel
electrophoresis, randomly amplified polymorphic DNA, multi-
locus variable number tandem repeat analysis and comparative
genomic hybridization microarray have been applied to further
differentiate strains within a toxinotype. However, such methods
are often technically demanding, difficult to standardize between
laboratories and sometimes produce poorly interpretable results,
as subtype and strain discrimination relies on differences in
observed electrophoretic or hybridization patterns [18,19,21–24].
In addition, these approaches often require high amounts of
genomic DNA obtained from pure bacterial cultures. The use of
high-yield random DNA amplification methods, combined to
sequence-based technologies targeting multiple molecular mark-
ers, is indispensable to overcome these limitations and obtain a
better overall resolution.
To overcome the problem of limiting amount of available DNA
in biological samples, whole genome amplification (WGA)
methods have been developed and successfully applied for a
number of genotyping assays [25–29]. In addition, high-density
resequencing microarrays (RMA) have emerged as a rapid
detection and molecular characterization tool for a broad range
of bacterial and viral agents [30],[31]. This technology has
demonstrated reliable detection of sequences differing up to 10–
15% from the prototype sequences on the array, enhancing the
spectrum of detection [31],[32]. In order to determine a target
nucleotide sequence, resequencing microarrays use closely over-
lapping (‘‘tiled’’) probe sets of 25 mers, which contain one
perfectly matched and three mismatched probes per base for both
strands of the target genes [33]. In the present study, we evaluated
the PathogenID v2.0 resequencing microarray, containing probes
for the detection and characterization of neurotoxin-producing
Clostridium species.
Figure 1. Neurotoxin gene cluster organization. In the gene cluster encoding the botulinum neurotoxin complex, the ‘‘ha cluster’’ appears to
be associated with type A1, A5, B, C, D and G bont genes, and the ‘‘orf-X cluster’’ with type A1, A2, A3, A4, F and E bont genes. 1Although the type A1
bont gene is mostly found in a ha cluster, it has been found associated with an orf-X cluster in some single toxin strains and in all bivalent strains
[18],[17].2The botR gene is in front of the ha genes in all toxinotype C and D strains.3The Ha33 gene is absent in all toxinotype G strains.4The botR
gene is absent in all toxinotype E strains
doi:10.1371/journal.pone.0067510.g001
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Results
Design of PathogenID microarray for Clostridium
detection and characterization
Detailed description of prototype sequences selected for
Clostridium detection and characterization is shown in table 1.
The array contains 4 tiled sequences targeting housekeeping genes
of Clostridium species: the complete rrs gene of C. botulinum
toxinotype A and partial rpoB genes of C. difficile, C. perfringens
and C. botulinum toxinotype A. In addition, the RMA includes 48
tiled sequences ranging from 149 to 200 nt in length, targeting
representative botulinum neurotoxin gene cluster components
(bont, ntnh, botR, ha17, ha70, ha33, orf-X1, orf-X2, orf-X3 and p47) of
toxinotypes A through G, as well as three toxinotype A subtypes
(A1, A2 and A3). Finally, it contains 19 tiled regions of 200 nt in
length for the detection and characterization of other specific
toxins produced by C. tetani, C. difficile, C. perfringens, C. sordellii, C.
septicum and C. oedematiens.
Resequencing of Clostridium with the PathogenID v2.0
microarray
The ability of the PathogenID v2.0 prototype sequences to
detect and subtype neurotoxin-producing C. botulinum strains was
assessed by performing a blind analysis of genomic DNA from
eleven well-characterized strains representative of the main
toxinotypes and subtypes. The observed call-rate for each tiled
sequence is detailed in table 2. The call-rates marked in bold
indicate sequences retained after filtering using the defined
threshold. The average base call rate was 91.6% (range 52.5–
100%) for strains for which genome sequence was identical to the
tiled sequences. The analysis of more distant genomic sequences
showed that these were successfully retrieved by RMA (Figure 2),
and retained after filtering when they presented up to 24.7%
divergence. The mean resequencing accuracy (correctly re-
sequenced bases in comparison to reference sequencing results
or database sequences) was 98.9% (range 87.1–100.0%). For all
strains analysed by the RMA and the automated filtering
approach, at least one sequence targeting a housekeeping gene
and one sequence targeting a neurotoxin gene cluster component
were successfully retrieved. For all bivalent strains analysed by
RMA, two distinct bont gene prototype sequences could be
retrieved: bont/B and/F sequences for strain 168.08 (toxinotype
Bf2), and bont/A and/B sequences for strains NCTC 2916
[toxinotype A1(B)] and 1430-11 [toxinotype A5(B9)]. Additionally,
sequences of two complete sets of ha and orf-X cluster components
were retrieved for strains 168.08 and NCTC 2916, but as expected
only sequences of ha cluster components were recovered for strain
1430-11. Finally, the RMA did not only allow the retrieval of
sequences specifically targeting BoNT gene cluster components
antp genes from the toxinotype of the strain analysed, but also
sequences targeting antp genes from other toxinotypes belonging to
the same taxonomic group. In particular, toxinotype B prototype
sequences (e.g. botR/B, ha17/B) were successfully retrieved for
strain Hall (toxinotype A), although these sequences show up to
11% divergence with the corresponding regions of the Hall strain
genome. Similarly, prototype sequences targeting toxinotype A1
antp genes were retrieved for the BL6 strain (toxinotype B), and
prototype sequences targeting toxinotypes A2 and A3 antp genes
were retrieved for the NCIB10658 strain (toxinotype F). This was
also observed for strains belonging to the C. botulinum taxonomic
group III strains, as both toxinotype C and toxinotype D antp
sequences were retrieved for strains 468 and 1873.
Automated filtering and taxonomic identification of
resequencing results
Automated filtering by TaxFinder using the defined parameters
retained between 7 and 27 C. botulinum sequences for each strain
(Table 2). Of the retained sequences, 98.8% (168/170) allowed
retrieval of at least one BLAST hit, and 99,4 % (167/168) of the
retrieved BLAST hits lead to correct taxonomic identification at
least to the toxinotype level. Moreover, blasting of all remaining
unfiltered C. botulinum prototype sequences (n = 358) did not return
any BLAST hit, indicating that no useful sequence was excluded.
For all reference strains the systematic BLAST strategy of retained
sequences obtained by the RMA allowed successful identification
of the clostridial species and taxonomic group using housekeeping
genes prototype sequences (Table 3). The strategy also permitted
in-depth characterization of all tested strains using the BoNT gene
cluster prototype sequences (Table 3). Moreover, BLAST analysis
allowed simultaneous typing of the neurotoxin up to the subtype
level, as for each strain a unique best hit or multiple best bacterial
hits were retrieved and corresponded to the correct subtype.
Finally, the turnaround time of this automated approach was
inferior to 2 hours, extensively decreasing the time needed for
filtering of sequences, blasting of retained sequences and result
analysis.
Identification, typing and characterization of a foodborne
botulism outbreak strain
To demonstrate the capacity of the RMA approach to detect C.
botulinum target sequences in the context of a foodborne outbreak,
DNA extracts from naturally contaminated food samples were
analysed. Food specimens were collected during the investigation
of a C. botulinum family outbreak in Corsica [34]. RMA was
performed on the DNA extract from a contaminated salad sample,
as well as the enrichment culture of the salad sample. For DNA
obtained directly from the salad specimen, a total of 286 bacterial
prototype sequences were retained, including 3 sequences
targeting C. botulinum genes (rrs, rpoB and ha33). However, none
led to correct taxonomic identification of the C. botulinum infecting
strain. For the DNA extract obtained from the enrichment culture
of the contaminated salad, a total of 15 C. botulinum prototype
sequences were retained after filtering, with call-rates ranging
between 46.7 to 97.7%. In addition, sequences targeting partial C.
perfringens-specific housekeeping genes (rpoB, gyrA, and parC) and
toxin genes (cpa, cpb2 and pfoR) were retrieved (call-rates ranging
between 70.1 and 98.3%). All filtered sequences led to the retrieval
of at least one BLAST hit and corresponding taxonomic identity.
The highest scoring BLAST results obtained for C.perfringens
prototype sequences retrieved by RMA all designated C. perfringens
strains as taxonomic hit (data not shown). The results of the
highest scoring BLAST alignment for each retained C. botulinum
sequence (total score, coverage and taxonomic identity) are
presented in figure 3. Strains belonging to the toxin subtype A2
were recognized as best hit for most of the retrieved sequences of
the neurotoxin gene cluster components. In addition, a gene
cluster type ha-/orfX+ was identified. Phylogenetic analysis of the
retrieved neurotoxin sequence with the corresponding sequences
of five strains representative of the different toxin A subtypes (A1
to A5), demonstrated an overall identity of 100% with the
neurotoxin sequence of the toxin subtype A2 reference strain. The
only mismatches in the multiple alignment were due to
unidentified bases (Figure 4).
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Table 1. Description of the sequences tiled on the PathogenID v2.0 microarray for the detection and characterization of BoNT-
producing clostridia.
Tiled sequence description Species Type Strain
Genbank
accession no. Position (nt)
length
(nt)
Housekeeping genes
rrs 16S rRNA C. botulinum A1 DSM1734 X73442.1 7..1513 1506
rpoB RNA polymerase (subunit b) C. botulinum A1 NCTC7272 Y16466.1 1249..1755 506
rpoB RNA polymerase (subunit b) C. perfringens ATCC13124 CP000246.1 2986532..2986026 506
rpoB RNA polymerase (subunit b) C. difficile 630 AM180355.1 91744..92253 509
Neurotoxin complex genes
bont/A1 Botulinum neurotoxin type A1 C. botulinum A1 Hall AF461540.1 11250..11450 200
bont/A2 Botulinum neurotoxin type A2 C. botulinum A2 Kyoto X73423.1 1771..1971 200
bont/B1 Botulinum neurotoxin type B1 C. botulinum B1 Okra AB232927.1 14210..14410 200
bont/Bnp Botulinum neurotoxin type Bnp C. botulinum Bnp ATCC25765 X71343.1 3586..3786 200
bont/C1 Botulinum neurotoxin type C1 C. botulinum C1 468 X53751.1 1876..2076 200
bont/D Botulinum neurotoxin type D C. botulinum D 1873 X54254.1 1697..1897 200
bont/E Botulinum neurotoxin type E C. botulinum E1 Beluga X62089.1 1213..1413 200
bont/F Botulinum neurotoxin type F C. botulinum F6 202 M92906.1 606..806 200
bont/G Botulinum neurotoxin type G C. botulinum G NCFB3012 X74162.1 1651..1851 200
ntnh/A1 Non-toxigenic non-hemagglutinin C. botulinum A1 Hall AF461540 8501..8695 194
ntnh/A2 Non-toxigenic non-hemagglutinin C. botulinum A2 Kyoto X87974 2453..2647 194
ntnh/A3 Non-toxigenic non-hemagglutinin C. botulinum A3 Mascarpone DQ310546 5690..5884 194
ntnh/Bp Non-toxigenic non-hemagglutinin C. botulinum B1 Okra AB232927 9649..9843 194
ntnh/C Non-toxigenic non-hemagglutinin C. botulinum C1 468 X72793 4757..4966 209
ntnh/D Non-toxigenic non-hemagglutinin C. botulinum D 1873 AB012112 4483..4692 209
ntnh/E Non-toxigenic non-hemagglutinin C. botulinum E Mashike D12697 2644..2838 194
ntnh/Ebut Non-toxigenic non-hemagglutinin C. butyricum E4 BL6340 D12739 2644..2838 194
ntnh/F Non-toxigenic non-hemagglutinin C. botulinum F6 202 S73676 2664..2858 194
ntnh/G Non-toxigenic non-hemagglutinin C. botulinum G ATCC27322 X87972 3390..3599 209
ha17/A Hemagglutinin 17 C. botulinum A1 Hall AF461540 4022..3822 200
ha17/Bp Hemagglutinin 17 C. botulinum B1 Okra AB232927 5170..4970 200
ha17/C Hemagglutinin 17 C. botulinum C1 468 X72793 3181..2981 200
ha17/D Hemagglutinin 17 C. botulinum D 1873 AB012112 2907..2707 200
ha17/G Hemagglutinin 17 C. botulinum G ATCC27322 X87972 1749..1600 149
ha70/A Hemagglutinin 70 C. botulinum A Hall AF461540 3166..3005 161
ha70/Bp Hemagglutinin 70 C. botulinum B1 Okra AB232927 4314..4153 161
ha70/C/D Hemagglutinin 70 C. botulinum C1 468 X72793 2337..2173 164
ha70/G Hemagglutinin 70 C. botulinum G ATCC27322 X87972 945..787 158
ha33/A Hemagglutinin 33 C. botulinum A1 Hall AF461540 4603..4403 200
ha33/Bp Hemagglutinin 33 C. botulinum B1 Okra AB232927 5748..5548 200
ha33/C/D Hemagglutinin 33 C. botulinum C1 468 X72793 3750..3550 200
orfX1/A2 Orf-X component 1 C. botulinum A2 Kyoto AB004778 524..315 209
orfX1/A3 Orf-X component 1 C. botulinum A3 Mascarpone DQ310546 1001..792 209
orfX1/E Orf-X component 1 C. botulinum E Iwanai D88418 1046..837 209
orfX2/A2 Orf-X component 2 C. botulinum A2 Kyoto AY497358 4619..4373 246
orfX2/E Orf-X component 2 C. botulinum E Iwanai D88418 256..10 246
orfX3/A2 Orf-X component 3 C. botulinum A2 Kyoto AY497358 2445..2236 209
botR/A1 Transcriptionnal regulator BotR C. botulinum A1 Hall AF461540 5502..5702 200
botR/A2 Transcriptionnal regulator BotR C. botulinum A2 Kyoto X96493 229..29 200
botR/A3 Transcriptionnal regulator BotR C. botulinum A3 Mascarpone DQ310546 1438..1238 200
botR/B Transcriptionnal regulator BotR C. botulinum B1 Okra AB232927 6653..6853 200
botR/C Transcriptionnal regulator BotR C. botulinum C1 468 X72793 512..712 200
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Discussion
Although botulism is quite rare in developed countries, recent
outbreaks have demonstrated the potential severity of this hazard
[35–40]. In such a context, rapid identification and characteriza-
tion of BoNT-producing clostridia in home-made or manufac-
tured food is a priority to stop the spread of botulism infections
and trace back the source of contamination [41–43]. While
identification of BoNT-encoding genes, using rapid nucleic-acid
detection tools, is usually satisfactory for molecular risk assessment
of BoNT-producing clostridia in food and environmental samples,
it is not sufficient to discriminate strains within a toxinotype for
source-tracing and molecular epidemiology [16]. For this reason,
recent recommendations have stated that new assays should be
able to detect variants for all toxinotypes, should be type-specific to
determine proper treatment, and should be sensitive to perform
risk assessment (NIAID Expert Panel on Botulism Diagnostics,
Bethesda Maryland, May 2003). The development of such
universal genetic characterization tools is hampered by the great
variability of the genomic background, the sequence of the bont
gene and the arrangement of the BoNT gene cluster of C. botulinum
strains, and therefore only available for a limited number of
strains.
In the present study, we designed and evaluated the
performances of a resequencing microarray combined with an
automated data approach for the simultaneous detection and
characterization of BoNT-producing clostridia. The described
RMA, designated PathogenID v2.0, and similar arrays have been
proven successful for the characterization of numerous bacteria
including Neisseria meningitidis, Streptococcus pyogenes, Streptococcus
pneumoniae, Bacillus anthracis, and several species of the Enterobacte-
riaceae family [30,44–46]. For the purpose of this study, prototype
sequences of housekeeping genes rrs and rpoB from clostridia
pathogenic for humans and most frequently associated with
outbreaks were incorporated in the RMA for identification of
clostridial species and lineages [47–49]. In addition, sequences
from the BoNT gene cluster were included for their involvement
in toxicity and usefulness for studying genetic variation [18,50,51].
The method was validated with DNA extracts from a
representative panel of reference C. botulinum strains. The obtained
Table 1. Cont.
Tiled sequence description Species Type Strain
Genbank
accession no. Position (nt)
length
(nt)
botR/D Transcriptionnal regulator BotR C. botulinum D 1873 AB012112 238..438 200
botR/G Transcriptionnal regulator BotR C. botulinum G ATCC27322 X87972 2595..2795 200
p47/A2 P 47 C. botulinum A2 Kyoto X96493 779..937 158
p47/A3 P 47 C. botulinum A3 Mascarpone DQ310546 1976..2134 158
p47/E P 47 C. botulinum E Iwanai D88418 1881..2081 200
p47/F P 47 C. botulinum F6 202 Y10770 946..1116 170
Clostridial toxin genes
C2 C2 toxin (component 1) C. botulinum (C)-203U28 D88982.1 838..1038 200
C2 C2 toxin (component 2) C. botulinum (C)-203U28 D88982.1 2245..2445 200
tent Tetanus neurotoxin C. tetani Massachusetts X04436.1 2026..2226 200
toxB Toxin B C. difficile VPI10463 X53138.1 1518..1718 200
toxB Toxin BF C. difficile 1470 Z23277.1 1183..1383 200
toxA Toxin A C. difficile VPI10463 X51797.1 2521..2721 200
cpa a-toxin C. perfringens S13 L43546.1 1317..1517 200
cpb1 b-toxin C. perfringens NCTC 8533 L13198.1 510..710 200
cpb2 b2-toxin C. perfringens Porcine CWC245 L77965.1 418..618 200
cpb2 b2-toxin C. perfringens Equine D21/98 AJ537535.1 199..399 200
cpb2 b2-toxin C. perfringens Bovine JGS4147 AY609175 151..351 200
etxD e-toxin D C. perfringens NCTC 8346 M95206.1 714..914 200
pfoR t-toxin (perfringolysin) C. perfringens lambda gt10 M81080.1 3529..3729 200
enterotoxin Enterotoxin C. perfringens NCTC8239 M98037.1 787..987 200
toxin-iota-a i-toxin (component Ia) C. perfringens NCIB10748 X73562.1 2254..2454 200
toxin-iota-b i-toxin (component Ib) C. perfringens NCIB10748 X73562.1 3515..3715 200
toxin-LT82 Lethal toxin 82 C. sordellii 82 X82638.1 1595..1795 200
a-toxin a-toxin C. septicum NCTC547 D17668.1 1062..1262 200
a-toxin a-novyi toxin C. oedematiens ATCC19402 Z48636.1 1286..1486 200
Quinolone-resistance determining regions
gyrA-qrdr Gyrase (subunit A) C. perfringens ATCC13124 CP000246.1 7269..7466 197
gyrA-qrdr Gyrase (subunit A) C. difficile 630 AM180355.1 6231..6428 197
parC-qrdr Topoisomerase (subunit IV) C. perfringens SM101 CP000312.1 2254972..2255160 188
doi:10.1371/journal.pone.0067510.t001
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results demonstrated that this approach has the potential to detect
neurotoxin-producing C. botulinum strains, but also phenotypically
related strains, by providing high quality sequence data. The
RMA approach reliably detected and characterized the neurotox-
in complex genetic determinants for all tested toxino-(sub)types,
including bivalent strains. Further analysis of resequencing results
showed that targeted sequences were successfully retrieved by the
RMA when they presented up to 24.7% divergence with the tiled
probes. This data supports the broadness of detection of the RMA,
as the divergence of the tiled probes compared to the respective
bont gene regions from all known toxin A, B, C, D, E and G
subtypes, and most toxin F subtypes, was calculated to be inferior
to 21%. Although the tiled bont/F sequence demonstrated
respectively 70.65% and 55.72% with the corresponding gene
region of the rare toxin subtypes F5 and F7, the high homology of
the additional housekeeping gene and antp gene sequences targeted
by the RMA should allow detection and correct identification of
these strains.
In addition to sequence divergence, differences in DNA extract
quality, genomic copy number variation, location of targeted
genomic regions and possible secondary structures, as well as the
G and C content of the tiled probes and the presence of
nonspecific nucleotide stretches could have affected genome
amplification and hybridization efficacy, possibly causing reduced
base-call rates. Nevertheless, this did not hamper the correct
identification and characterization of the analyzed strains.
Subsequently, the pathogenID v2.0 was used to identify C.
botulinum strains in contaminated food specimens. The analysis of
the DNA extract obtained directly from these specimens by the
RMA did not permit quality resequencing of the infecting C.
botulinum strain sequences. These results are due to the presence of
numerous cultivable and non-cultivable environmental bacteria
naturally present in food, competing with the C. botulinum strain
during the whole genome amplification step, and subsequently
increasing the noise level observed at the time of the analysis.
Nevertheless, a 48 h enrichment culture of the contaminated food
samples was sufficient to successfully detect and characterize the
infecting C. botulinum strain as well as a co-cultured C. perfringens
strain. The results obtained by BLASTing and phylogenetic
analysis of the retrieved bont sequence, as well as the character-
ization of the BoNT gene cluster components, classified the strain
as a C. botulinum toxinotype A2. Moreover, the examination of the
taxonomic BLAST hits indicated a close relatedness to strain
Mascarpone. As the analysis was performed with a partial
sequence of the bont gene (200 nt), containing 4% unidentified
bases, misclassification of the toxin subtype may have occurred.
However, this was unlikely as the retained sequence contained
specific determinants found only in bont/A2 genes, and unidenti-
fied residues were located in regions that are not discriminant for
subtype differentiation. The C. botulinum strain detected by RMA
could be isolated from the food sample, and confirmed as subtype
A2 by sequencing the specifically PCR-amplified bont gene
(genbank accession number JQ954970).
The many advantages of using DNA microarrays for charac-
terization of bacteria have been discussed in the past and can be
applied to this assay. First, the genetic characterization results can
Figure 2. Detection spectrum of the PathogenID_v2.0 according to the nucleotide diversity of the tested BoNT-producing strains.
The spectrum of detection of BoNT-producing clostridia by the PathogenID v2.0 was assessed using 9 well-characterized strains representative of all
toxinotypes and several toxin A subtypes. Each sequence obtained by the RMA for which the percentage of nucleotide divergence compared to the
corresponding tiled sequence is known (n= 118), is indicated by a blue diamond, and presented according to the percentage of nucleotide bases
determined by the RMA (call rate). The linear association between these two parameters is shown, and demonstrates a good correlation (correlation
coefficient R2 of 0.79).
doi:10.1371/journal.pone.0067510.g002
Detection of Botulinum Toxin by Resequencing Array
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e67510
Table 2. Call-rates observed for the different C. botulinum sequences retrieved by the PathogenID V2.0 microarray for all tested
bacterial strains.
Tiled C. botulinum
sequence Clostridium botulinum toxin subtype and strain
A1 A5(B9) A1(B) A3 B2 Bf2 F6 E1 C1 D G
Hall 1430.11 2916
Loch
Maree BL6 168.08 NCIB 10658 K16 468 1873 NCIB 10714
Housekeeping genes
rrs A1 88,1 83,5 83,9 80,6 90,7 21,5 85,1 69,8 71,7 61,7 69,2
RpoB A1 96,5 96,3 94,6 91,1 90,7 90,7 95,2 16,4 23,6 15,7 16,4
Neurotoxin genes
bont/A1 97,2 87,0 97,7 23,7 6,2 8,5 11,9 7,3 16,4 11,3 7,9
bont/A2 18,1 12,4 21,5 88,7 8,5 9,0 16,4 7,9 7,9 2,3 7,9
bont/B1 14,7 18,1 78,5 11,3 19,8 88,7 11,3 10,2 13,6 1,7 10,7
bont/Bnp 10,2 27,1 35,6 10,7 20,3 35,6 10,2 3,4 8,5 2,8 11,3
bont/C1 14,1 8,5 10,7 14,1 4,5 7,3 16,9 10,7 99,4 1,1 11,9
bont/D 13,6 2,8 12,4 21,5 4,5 5,7 19,2 15,3 13,6 84,7 12,4
bont/E 6,8 1,7 2,8 9,6 4,5 1,1 6,2 67,2 5,6 0,6 2,3
bont/F 16,4 4,0 16,9 23,7 11,9 49,2 53,1 11,3 13,6 3,4 8,5
bont/G 11,9 7,9 11,9 11,3 5,6 9,0 11,3 8,5 10,2 3,4 76,8
Non-toxin non-hemagglutinin gene
ntnh/A1 99,4 81,9 90,6 75,4 10,5 78,4 55,6 9,4 8,2 1,2 6,4
ntnh/A2 86,0 78,4 87,7 60,8 15,8 76,6 80,7 13,5 7,6 1,2 8,2
ntnh/A3 70,2 73,7 81,3 69,6 8,8 81,3 48,5 8,2 7,0 0,6 7,0
ntnh/Bp 11,1 2,3 14,6 12,3 97,1 98,2 19,9 8,8 20,5 4,1 29,2
ntnh/C 26,9 11,8 17,2 17,7 16,1 9,7 13,4 14,5 96,2 72,0 9,7
ntnh/D 32,8 21,0 24,2 19,4 22,0 17,2 13,4 14,5 96,2 79,6 9,1
ntnh/E 21,1 12,3 24,0 26,3 7,6 9,9 15,8 87,1 15,8 2,3 11,1
ntnh/Ebut 21,6 11,7 24,0 26,3 6,4 9,9 15,2 86,5 15,2 1,8 11,1
ntnh/F 45,0 38,6 39,8 39,8 9,4 43,3 33,3 22,8 14,0 1,8 9,4
ntnh/G 27,4 14,5 22,6 22,0 16,1 15,1 14,0 7,0 24,2 5,9 64,5
ha-cluster components
ha70/A 94,9 63,8 91,3 13,0 76,8 96,4 9,4 3,6 9,4 0,0 7,2
ha70/Bp 88,4 77,5 85,5 13,8 84,8 92,0 6,5 3,6 8,0 0,7 8,0
ha70/C/D 7,8 4,3 7,1 13,5 5,7 7,1 5,7 5,7 100,0 79,4 6,4
ha70/G 14,8 23,0 15,6 10,4 23,0 11,9 12,6 5,2 25,2 5,2 45,9
ha17/A 98,9 80,8 97,2 15,8 86,4 96,6 15,8 11,3 19,8 8,5 11,9
ha17/Bp 84,7 84,2 82,5 15,8 84,2 84,2 14,7 13,0 19,2 9,6 13,0
ha17/C 10,7 7,9 5,6 18,1 8,5 7,3 10,2 7,3 100,0 89,3 7,9
ha17/D 11,3 8,5 4,5 16,4 8,5 6,8 7,9 6,2 100,0 84,7 9,0
ha17/G 11,1 3,2 4,8 9,5 3,2 5,6 5,6 6,3 9,5 0,0 57,9
ha33/A 96,0 45,2 78,5 14,1 49,2 85,3 8,5 6,2 13,6 4,0 9,0
ha33/Bp 30,5 30,5 33,3 7,3 55,4 41,8 6,8 8,5 6,8 2,3 4,5
ha33/C/D 19,2 5,1 15,3 10,7 9,0 4,0 10,7 7,9 99,4 0,6 9,0
botR/A1 93,2 59,3 74,6 18,1 83,6 89,3 13,6 5,1 16,4 0,6 10,7
botR/Bp 81,9 68,4 88,1 20,3 67,2 93,2 13,0 7,3 17,5 0,6 10,7
botR/C 7,9 5,1 14,1 11,3 9,6 13,6 14,1 7,3 98,9 45,2 7,3
botR/D 9,0 6,8 13,6 11,3 8,5 11,9 15,3 7,3 98,9 52,5 8,5
botR/G 15,8 4,5 11,9 11,3 9,0 2,3 7,9 4,5 13,0 0,6 46,9
orfX-cluster components
orfX1-A2 5,4 1,1 57,5 90,3 6,5 59,7 73,7 3,8 7,5 3,8 6,5
orfX2-A2 14,8 4,5 90,1 88,8 9,0 68,2 83,9 11,2 10,8 6,7 12,6
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be used to support epidemiological associations in outbreaks
involving a large number of samples or those from multiple
geographical locations[17]. Secondly, they can be used to trace or
confirm the source of an outbreak or to perform environmental
risk assessments [52,53]. In the specific context of botulism, the
results provided by DNA microarray can further serve to design
specific primers for rapid nucleic acid detection methods, and
allow a preliminary differentiation of the strains before applying
more laborious genotyping methods such as PFGE [17].
In addition to these advantages, the specific design and
properties of high-density RMAs allow the detection of a broad
range of strains, including potentially emerging variants [44,54].
Firstly, the use of closely overlapping 25 nt probe sets in the RMA
approach instead of unique probes to cover a target region of 100–
500 nt increases the chance for hybridization of divergent target
DNA to the array. Indeed, studies using focused or comparative
genomic hybridization microarrays have reported a maximum
value of 15–18% nucleotide sequence divergence of probe regions
for positive microarray detection of C. botulinum genomic DNA, as
compared to 24.7% for the RMA described here [17–19,24]. In
addition, the relatedness between strains can be quantified more
precisely by using a sequence-based approach such as the RMA,
rather than by analysis of differences in hybridization patterns
provided by classic microarrays. This is particularly important in
the case of botulism, as the frequent occurrence of gene
recombination, insertion and transfer observed between Clostridium
strains indicate that such events are likely to occur again. In such a
case, the sequence information provided by the RMA will be most
valuable for the characterization of the emerging variants and the
development of improved rapid detection tools. This also
emphasizes the need for bacterial culture isolates as well as well-
Table 2. Cont.
Tiled C. botulinum
sequence Clostridium botulinum toxin subtype and strain
A1 A5(B9) A1(B) A3 B2 Bf2 F6 E1 C1 D G
Hall 1430.11 2916
Loch
Maree BL6 168.08 NCIB 10658 K16 468 1873 NCIB 10714
orfX3-A2 9,7 2,2 87,1 97,8 10,8 96,8 86,6 14,0 20,4 7,5 9,7
orfX1-A3 8,6 5,4 78,0 61,3 7,5 41,9 54,3 5,4 7,5 1,6 5,9
orfX1-E 6,5 5,9 9,1 11,3 3,2 9,1 7,5 68,3 8,1 7,5 6,5
orfX2-E 9,9 5,4 15,2 22,4 6,3 7,2 17,0 71,3 10,3 1,8 7,2
botR/A2 9,6 1,1 39,0 74,0 8,5 62,1 42,9 2,8 10,2 2,3 4,5
botR/A3 8,5 0,6 68,4 41,8 2,8 69,5 39,5 5,1 10,2 1,7 6,2
p47/A2 9,6 3,7 40,7 31,1 6,7 36,3 36,3 6,7 14,1 1,5 8,1
p47/A3 10,4 1,5 90,4 61,5 6,7 69,6 72,6 5,9 15,6 1,5 7,4
p47/E 5,1 1,1 21,5 33,3 2,3 23,2 19,8 80,8 4,0 0,0 2,3
p47/F 8,8 0,7 8,8 6,1 4,8 95,9 19,0 6,1 8,8 1,4 12,9
Sequences retained after filtering using the defined threshold are designated in bold.
doi:10.1371/journal.pone.0067510.t002
Table 3. Identification and characterization of C. botulinum strains based on the sequences retrieved by the PathogenID v2.0
microarray and the BLAST analysis results.
Strain Toxin subtype PathogenID v2.0 RMA results
Taxonomic identification Neurotoxin subtype
BoNT gene cluster
characterization
Hall A1 C. botulinum group I A1 ha+/OrfX2
1430.11 A5(B9) C. botulinum group I A5, B ha+/OrfX2
2916 A1(B) C. botulinum group I A1, bivalent B ha+/OrfX+
Loch Maree A3 C. botulinum group I A3 ha-/OrfX+
BL6 B2 C. botulinum group I proteolytic B ha+/OrfX2
168.08 Bf2 C. botulinum group I bivalent B, F2 ha+/OrfX+
NCIB10658 F6 C. botulinum group I proteolytic F ha-/OrfX+
K16 E1 C. botulinum group II E1 ha-/OrfX+
468 C1 C. botulinum group III C1 ha+/OrfX2
1873 D C. botulinum group III D ha+/OrfX2
NCIB10714 G C. botulinum group IV G ha+/OrfX2
doi:10.1371/journal.pone.0067510.t003
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characterized microbial strain collections, in order to monitor the
molecular evolution of the strains.
The unique design of the PathogenID v2.0 array allows the
simultaneous detection and characterization of 48 sequences
targeting the BoNT gene cluster components. These sequences
could easily be used in the design of specific RMAs with reduced
probe densities by decreasing the number of sequences, thereby
diminishing production costs and computing time. Using standard
methods to obtain the same level of resolution would imply the use
of specific PCRs followed by Sanger sequencing. Although these
assays are cheaper as standalone tests, running enough of them to
cover the same number of genes with a single sample quickly
Figure 3. C. botulinum sequences retrieved by the PathogenID_v2.0 in contaminated food and BLAST analysis results. A schematic
representation of the BoNT gene cluster sequences obtained by the RMA for the enrichment culture of the contaminated salad specimen is shown.
The orientation and arrangement of these components were reproduced after Franciosa et al [59]. For each component, the highest call-rate
observed and the results of the best retrieved BLAST hit(s) (defined as the BLAST hit demonstrating the highest total score) are given i.e. the number
of best hits retrieved, as well as the corresponding query sequence coverage, total score, and taxonomy.
doi:10.1371/journal.pone.0067510.g003
Figure 4. Phylogenetic tree of the bont/A sequence retrieved in contaminated food and several toxinotype A strains. A neighbor-
joining tree was constructed based on the bont/A sequence retrieved by the RMA for the enrichment culture of the C. botulinum strain in a naturally
contaminated salad specimen, and the corresponding sequences of 6 strains representative of 5 known C. botulinum toxinotype A subtypes: strain
Hall (A1), NCTC 2916 (A[B]), Kyoto (A2), Loch Maree (A3), 657 (Ba4) and A661222 (A5). Bootstrap values and genetic distance (bar) are shown. The
Genbank accession number of each strain is indicated in parentheses. The bont sequence obtained from the contaminated salad specimen is marked
in bold.
doi:10.1371/journal.pone.0067510.g004
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surpasses the RMA in cost, time and logistical complexity of
running the analysis. Moreover these methods rely on sequence-
specific primer hybridization for target DNA amplification instead
of random hexamers for unbiased whole genome amplification,
and may therefore fail to amplify and detect emerging variants.
Other technologies with universal coverage could be used, such as
high-throughput sequencing, however they are still much more
laborious and expensive. Finally, the use of an automated
approach allows an unbiased, exhaustive and rapid retrieval of
taxonomic results.
In summary, the RMA allowed successful detection and fine
characterization of neurotoxin-producing clostridia in both pure
and polymicrobial cultures. The RMA approach, combined with
the automated filtering and retrieval of taxonomic identities,
allowed efficient and accurate subtyping of the neurotoxin and
detailed characterization of the BoNT gene cluster components.
This assay will be used as a higher echelon component in a
diagnostics and surveillance pipeline. Importantly, it will be used
in further studies to characterise potential outbreak related strains,
but also environment isolates, in order to obtain a better picture of
the molecular epidemiology of BoNT-producing clostridia.
Materials and Methods
Design of the Pathogen ID v2.0 resequencing microarray
(RMA)
The second generation of a broad-spectrum resequencing
microarray (RMA) was used in this study: the PathogenID v2.0
array, able to detect 124 bacteria, 126 viruses and 673 genes
involved in toxin production, pathogenicity or antibiotic resistance
[31]. This array included specific housekeeping genes, namely rrs
and rpoB, for detection and characterization of clostridial species.
In addition, it included prototype sequences of each component of
the neurotoxin gene cluster from all known toxinotypes, as well as
several subtypes. Tiled probes targeting these genes were selected
using multiple sequence alignments of genome sequences from
various toxin subtypes available in GenBank during the time of the
RMA design, in order to select conserved regions within
toxinotypes for optimal hybridization efficacy. Additional probes
were added to improve the detection of specific subtypes, if strains
demonstrated sequence variation within the selected probe region.
In addition, the bont/C and bont/D sequences tiled on the array
were specifically designed to maximize the probability of detection
of mosaic C. botulinum toxinotype C/D or D/C strains, by targeting
regions highly homologous to either mosaic bont/C/D or bont/D/C
genes. Finally, 19 additional sequences were tiled on the array for
detection of a large panel of clostridial toxins other than
neurotoxins.
Bacterial strains and biological samples analysed
Eleven well-characterized C. botulinum strains belonging to
toxinotypes A through G served as reference: strains Hall (type
A1), 1430-11 [type A5(B9)], NCTC 2916 [type A1(B)], Loch
Maree (type A3), BL6 (type B2), 161.08 (type Bf2), NCIB 10658
(type F6), K16 (type E1), 468 (type C1), 1873 (type D) and NCIB
10714 (type G). The characteristics and origin of most strains have
been described elsewhere. The C. botulinum type A5(B) strain 1430-
11 was isolated from contaminated commercial food (pasta). The
C. botulinum strain 161.08 was isolated from a foodborne botulism
case. Pure cultures of Clostridium spp. strains were performed as
described previously [55]. Genome sequences from reference
strains were retrieved from the genbank database. The bont
sequences for strain 1430-11 (genbank accession numbers
KC683799 and KC683800) and strain 161.08 (genbank accession
numbers KC471328 and KC471329) were obtained by sanger
sequencing of specifically PCR-amplified bont genes and deposited
in genbank.
Biological samples included a naturally contaminated food
specimen (salad) and a 48 h enrichment culture of this food sample
in Fortified Cooked Meat Medium (FCMM) at 37uC in anaerobic
conditions [56]. Presence of C.botulinum toxinotype A in the food
samples was confirmed by SYBR green real-time PCR with
primers P1646 (59-TCTTACGCGAAATGGTTATGG-39) and
P1647 (59-TGCCTGCACCTAAAAGAGGA-39) for bont/A gene,
P1648 (59-CCTGGGCCAGTTTTAAATGA-39) and P1649 (59-
GCGCCTTTGTTTTCTTGAAC-39) for bont/B gene, P1650 (59-
GTGCCCGAAGGTGAAAATAA-39) and P1651 (59-
TAATGCTGCTTGCACAGGTT-39) for bont/E gene, P2107
(59-TGCACAATGAATTTTCAAAACA-39) and P2108 (59-
TCCAAAAGCATCCATTACTGC-39) for bont/F gene. Real
time PCR was performed in a total volume of 25 ml containing
12.5 ml of 26concentration of iQ SYBR green Supermix (Biorad),
5 pmole of each primer, 5 ml of template DNA and 7.3 ml of
DNase-RNase free ditilled water (Gibco). Amplifications were
carried out on a CFX96 Real Time System (Biorad) using 96-well
microwell plates and according to the following temperature
profile: one cycle of 95uC for 10 minutes, 40 cycles of 95uC for 15
sec and 60uC for 30 sec with fluorescence signal capture at the end
of each 60uC step, an extension phase of 1 cycle at 95uC for
60 sec, 60uC for 60 sec and 95uC for 60 sec, followed by a default
melt (disassociation) stage.
Extraction and amplification of bacterial DNA
Total genomic DNA was isolated from C. botulinum cultures by
lysozyme and proteinase K treatment as described previously [57].
DNA extraction from food samples was performed with Power-
food Microbial DNA isolation kit (MoBio Laboratories Inc)
according to the manufacturer’s recommendations. After extrac-
tion, DNA was amplified using the whole genome amplification
(WGA) protocol (RepliG Midi kit, Qiagen) as described previously
[54].
Resequencing microarray assay
The amplification products obtained from genomic DNA by
WGA were quantified by Quantit BR (Invitrogen) according to the
manufacturer’s instructions. A recommended amount of target
DNA was fragmented and labeled according to the GeneChip
Resequencing Assay manual (Affymetrix). The obtained products
were coded with unrelated numbers by a non-observer to ensure
that the study was performed blindly. The microarray hybridiza-
tion process was carried out according to the protocol recom-
mended by the manufacturer (Affymetrix). The details and
parameter settings for the data analysis (essentially conversion of
raw image files obtained from scanning of the microarrays into
FASTA files containing the sequences of called bases for each tiled
region of the microarray) have been described previously [54].
The base call rate refers to the percentage of base calls generated
from the full-length tiled sequence.
Automated data analysis
A Perl-based program, designated ‘‘TaxFinder’’, was used for
the automated analysis of re-sequencing data provided by
PathogenID v2.0. The program read the FASTA file generated
for each sample, which contains all the sequences read by the
GSEQ software (Affymetrix) from the hybridization results. A
filtering process, based on the one described by Malanoski et al.
[58] was applied to these sequences. For each sequence,
TaxFinder considers the Nb first bases of the sequence, Nb
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defined by the user in the beginning of the experiment and
corresponding to the minimal length accepted for the sequence to
keep. If the percentage of No-call in this fragment is inferior to an
elongation threshold defined by the user, a base is added to the
fragment and the percentage of No-call is recalculated. As soon as
it is higher that the elongation threshold, the No-call at the ends of
the fragment are removed. If the length of the nucleotide fragment
is still higher than the minimal threshold established, then it is
conserved. If the percentage is higher than the threshold, the
fragment is skipped, and the program considers the fragment of
size Nb and starting position one base upstream than the
precedent fragment. This process is reiterated until the end of
the sequence is reached. In this study, sequences that did not
contain subsequences with a minimum nucleotide length of 20 nt
and a maximum undetermined nucleotide content of 10% were
discarded. Filtered sequences individually underwent a blastn
analysis to search for sequence homologues in the NCBI
nucleotide collection (nr/nt database) with adjusted settings to
restrict the search to bacteria entries. Blast + application
distributed by NCBI is used for the automated blast research
(http://www.ncbi.nlm.nih.gov/books/NBK1763/). The following
algorithm parameters were modified: the expected value cut-off
was fixed to 100, the minimum word size was set to 7 and the
upper limit of displayed descriptions of database sequences per
query was decreased to 50. The best BLAST hits were classified
according to their total score (the sum of the high-scoring segment
pairs) and their corresponding taxonomies were retrieved from the
NCBI Taxonomy database. When several hits obtained the
highest total score, the script automatically retrieved the
taxonomies of the 10 first BLAST hits.
Phylogenetic analysis
The resulting bont sequence obtained from the enrichment
culture of the C. botulinum strain in a contaminated food specimen
was compared with the corresponding bont sequences of reference
strains from the 5 known C. botulinum toxinotype A subtypes
(GenBank accessed 21/02/2013). Multiple sequence alignment
was performed using the CLC Bio software and checked for
accuracy by eye. A neighbor-joining tree of these sequences was
constructed using the Jukes-Cantor method with the SeaView
v4.2.1 software. The level of support for each node is provided by
100 bootstrap replications.
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